PhoenixBio Co.,Ltd.【JP:6190】Stock Price

Phoenix Bio is a company primarily engaged in the PXB Mouse business. This business provides contract testing services for pharmaceutical development using PXB mice, which are chimeric mice containing human liver cells. Phoenix Bio operates this business together with three consolidated subsidiaries as a single business segment.

PXB mice are specialized mice in which over 70% of the mouse liver has been replaced with human liver cells. Leveraging this technology, Phoenix Bio provides testing services in pharmaceutical preclinical trials to predict human drug metabolism. Specifically, the company conducts dosage studies on drug candidate substances for pharmaceutical companies to confirm drug safety and efficacy.

Additionally, PXB mice are used in research on viruses that infect only human liver cells, such as hepatitis B virus and hepatitis C virus. This plays an important role in the development of antiviral drugs. Through these tests, Phoenix Bio contributes to pharmaceutical companies and research institutions.

Phoenix Bio's main services include DMPK/Tox testing, hepatitis testing, and PXB-cells sales. DMPK/Tox testing evaluates drug pharmacokinetics and toxicity, predicting drug metabolism in the liver and hepatotoxic responses. Hepatitis testing uses PXB mice to evaluate the efficacy of new drug candidate compounds, particularly contributing to the development of anti-hepatitis drugs.

Furthermore, Phoenix Bio sells PXB-cells, fresh human liver cells derived from PXB mice. This enables drug discovery researchers to conduct experiments while maintaining the original functions of liver cells, contributing to research efficiency. PXB-cells can be supplied consistently, allowing researchers to conduct experiments tailored to their needs.

Phoenix Bio aims to contribute to 21st-century healthcare by leveraging its proprietary cell technology to advance practical applications of new medical technologies. The company has developed technology to maintain human cell function while enabling large-scale proliferation, and is expanding its PXB mouse business based on this technology.

The company provides contract testing services for pharmaceutical development using PXB mice, with a particular focus on business expansion in the North American market. It established Phoenix Bio USA Corporation in 2010 and is advancing its international operations by strengthening partnerships with North American pharmaceutical companies and CROs.

Recently, new drug modalities have gained attention in pharmaceutical development, and Phoenix Bio's PXB mice are recognized as a valuable tool for evaluating human-specific proteins and nucleic acids. The company is working to increase product awareness through collaborative research with universities and pharmaceutical companies both domestically and internationally.

To meet growing demand for PXB mice, Phoenix Bio is implementing production expansion plans through outsourced breeding arrangements. From an animal welfare perspective, the company is establishing facilities and breeding methods that comply with international animal management standards and is pursuing AAALAC International accreditation.

Additionally, the company recognizes the importance of in vitro testing and has launched related products such as PXB-cells. It is strengthening research and development in emerging technologies such as Microphysiological Systems (MPS) and developing products aligned with U.S. market trends.

Phoenix Bio prioritizes obtaining data that demonstrates the utility of PXB mice and PXB-cells as evaluation tools for next-generation pharmaceuticals, and seeks to develop new markets through collaborative research and business partnerships. In particular, the company views sales in the safety assessment field as a key performance indicator for business expansion.